Alan Cohen, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1245203371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,196,302 of the $1,374,248 with a category attached, or 87.1%. 53 manufacturers reported payments, led by Lilly USA, LLC at 41.3% of the total. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,726 payments — averaging $796.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$567K
- Amgen$238K
- Novo Nordisk$199K
- Sanofi-aventis U.S. LLC$188K
- Neurocrine Biosciences, Inc.$51K
- Boehringer Ingelheim$34K
- plus $98K from 47 others
Across 31 payments — averaging $3067.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$84K
- Radius Health, Inc.$8K
- Boehringer Ingelheim International GmbH$2K
- Merck$1K
What the payments were for
- Consulting fees$42,9173%
- Speaking & faculty fees$1,196,30287%
- Travel & lodging$106,3368%
- Food & beverage$28,3762%
- Education$3180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$258,568
- MOUNJARO$166,603
- TZIELD$133,022
- EVENITY$118,556
- Prolia$116,845
- JARDIANCE$103,686
- Ozempic$90,850
- RYBELSUS$65,840
- CRENESSITY$40,999
- SOLIQUA 100/33$35,288
- Kerendia$30,821
- Tymlos$22,503
- FARXIGA$20,878
- Tresiba$16,288
- STEGLATRO$10,605
- TOUJEO$9,488
- Norditropin$6,248
- Tirosint$4,000
- Xultophy 100/3.6$2,210
- Korlym$875
How this compares
$1,374,248 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 175 | $216,908 |
| OzempicSemaglutide | 133 | $188,679 |
| JardianceEmpagliflozin | 176 | $185,095 |
| TrulicityDulaglutide | 29 | $51,982 |
| FarxigaDapagliflozin Propanediol | 35 | $44,906 |
| JanuviaSitagliptin Phosphate | 50 | $44,111 |
| KerendiaFinerenone | 36 | $37,249 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $35,609 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $25,860 |
| RybelsusSemaglutide | 21 | $23,213 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $19,912 |
| TradjentaLinagliptin | 20 | $19,370 |
| ProliaDenosumab | 11 | $18,905 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $18,543 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $17,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $567,438 | $273,118223 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $33,590 | $222,175211 claims |
| Novo NordiskOzempic, Rybelsus | $198,995 | $211,893154 claims |
| AstraZenecaFarxiga | $21,598 | $44,90635 claims |
| MerckJanuvia | $11,001 | $44,11150 claims |
| BayerKerendia | $31,165 | $37,24936 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $187,514 | $25,86024 claims |
| AmgenProlia | $237,851 | $18,90511 claims |
| AbbVieSynthroid | $414 | $8,276101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Maher GhawjiMemphis$13K
- Yunna JiangMemphis$12K
- Rabia RehmanMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.